Daniel D. Von Hoff

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations

Medicine, Oncology, Pharmacology +13

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations

Medicine, Oncology, Pharmacotherapy +16

Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

Daniel D. Von Hoff · Annals of Internal Medicine · 1979 · 2.4K citations

Medicine, Pharmacology, Pharmacotherapy +15

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

Paolo P. Provenzano, Carlos Cuevas, Amy Chang et al. · Cancer Cell · 2012 · 2.1K citations · Full text

Medicine, Cancer Biology, Oncology +14

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +16